enGene enters $100M at-the-market equity facility with Leerink Partners

enGene Therapeutics Inc.

New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
Prior Open Market Sale Agreement with Jefferies LLC terminated on March 6, 2026; no shares sold and no penalties.
Leerink will receive a commission of up to 3.0% of gross proceeds; Company may reimburse certain expenses.
Shares will be sold under Rule 415(a)(4); Company not obligated to sell any shares.
No shares offered or sold in Canada under the new agreement.

item 1.01item 1.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.